Page 'Sub' Navigation:
Page Path 'Breadcrumb':
Kimberly J. Manhard
Ms. Manhard was appointed as our Senior Vice President of Regulatory Affairs and Development Operations in December, 2006. Prior to that, Ms. Manhard was President of her own consultancy since 2003, specializing in the development of small molecules intended for the treatment of antiviral, oncology, central nervous system (CNS), and gastrointestinal indications, and was responsible for filing five initial US INDs and multiple clinical trial applications in the European Union and Canada. Prior to starting her consultancy, Ms. Manhard was Vice President of Regulatory Affairs for Exelixis, Inc. Previously, she was Head of Regulatory Affairs for Agouron Global Commercial Operations (a Pfizer company) supporting marketed HIV products. She joined Agouron in 1996 as Director of Regulatory Affairs responsible for anticancer and antiviral products, including nelfinavir (Viracept®). Prior to Agouron, she was with Bristol-Myers Squibb for over five years in Regulatory Affairs and was responsible for investigational oncology compounds, including paclitaxel (Taxol®), and infectious disease compounds, including didanosine (Videx®) and stavudine (Zerit®). Ms Manhard began her industry career in Clinical Research with Eli Lilly and Company and G.H. Besselaar Associates (Covance). She earned a BS in Zoology and a BA in French from the University of Florida.
Senior Vice President, Regulatory Affairs and Development Operations
Colin E. Rowlings, PhD
Dr. Rowlings was appointed as our Senior Vice President of Pharmaceutical Sciences in April, 2007. Dr. Rowlings has been a consultant since 2005 and became President of his own consulting company in early 2007. Prior to this, Dr. Rowlings was Senior Vice President of Pharmaceutical Research and Development at Advancis Pharmaceutical Corp. Dr. Rowlings was at Advancis for four years and led the Pharmaceutical Research, Pharmaceutical Development Operations, Analytical Sciences, Project Management and Quality Assurance organizations. From 1997 to 2001, he was Director of Pharmaceutical Development at Agouron Pharmaceuticals, Inc. (now Pfizer, Inc.). Dr. Rowlings has also worked in Product Development at Rhone-Poulenc Rorer (now sanofi-aventis) and Eli Lilly and Company. Dr. Rowlings has a Bachelor of Pharmacy degree from the University of Queensland, Australia and a PhD in Pharmaceutics from the University of Iowa.
Senior Vice President, Pharmaceutical Sciences